// App-Quantinova.ai

8566 : Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study.

Researchers

Presenter

  • Sanjay Popat

Principal Investigators

  • Nicola Steele

  • Anna K. Nowak

  • Silvia Novello

  • Laurent Greillier

  • Martin Reck

  • Tom John

  • Paul Taylor

  • Natasha B. Leighl

  • Giovanni Luca Ceresoli

  • Jens Benn Srensen

  • Nick Pavlakis

  • David Planchard

  • Brett Gordon Maxwell Hughes

  • Julien Mazieres

  • Mark A. Socinski

  • Hannes Buchner

  • Jose Barrueco

  • Giorgio V. Scagliotti

Medical Centers

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • SS Antonio e Biagio General Hospital, Department of Oncology, Via Venezia 16, Alessandria, Italy

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, Crawley, Australia

  • University of Turin, Department of Oncology, S. Luigi Hospital, Torino, Italy

  • Assistance Publique Hopitaux de Marseille, Aix Marseille University, Marseille, France

  • Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany

  • Olivia Newton-John Cancer Research Institute/ Austin Health, Heidelberg, Australia

  • Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Cliniche Humanitas Gavazzeni, Department of Oncology, Bergamo, Italy

  • Rigshospitalet Blegdamsvej 9, 2100 Kbenhavn , Denmark

  • Northern Cancer Institute, St Leonards, Sydney, Australia

  • Gustave Roussy Cancer Campus, Department of Medical Oncology, Villejuif, France

  • The Prince Charles Hospital, Brisbane, Australia

  • Hospital Larrey, Onco, Chemin de Pouvourville, Toulouse, France

  • Florida Hospital Cancer Institute, Orlando, FL

  • Staburo GmbH, Munich, Germany

  • Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT

Locations

  • Canada

  • Italy

  • Germany

  • United Kingdom

  • Australia

  • United States

  • France

  • Denmark

Companies

  • Staburo GmbH

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Cancer antigen 15-3

Drug/Treatment

  • Nintedanib

  • Pemetrexed

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • II/III

Study Id's

  • NCT01907100

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved